Bioforce Nanosciences Holdings Quick Ratio (BFNH) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
BIOFORCE NANOSCIENCES HOLDINGS, INC.  (OTC: BFNH)

Bioforce Nanosciences Holdings's Quick Ratio

BFNH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 0 a new company low.

Within Laboratory Analytical Instruments industry BIOFORCE NANOSCIENCES HOLDINGS, INC. booked the highest Quick Ratio than Bioforce Nanosciences Holdings in the second quarter 2026. While total ranking remained the same in the Q2 2026 compared to the first quarter 2026 at no. 14.

Explain Quick Ratio?
How much Cash & cash equivalents BFNH´s has?
What are BFNH´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BFNH Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -74.13 % 169.59 % -74.46 % -77.48 % -81.93 %
Y / Y Cash & cash equivalent Change -65.89 % -54.35 % -11.11 % -50 % 28.57 %
Quick Ratio MRQ 0 0.01 0 0 0
BFNH's Total Ranking # 14 # 14 # # #
Seq. Current Liabilities Change -86.49 % 21.16 % 19.77 % 31.98 % 40.76 %
Seq. Cash & cash equivalent Change -95.13 % 687.5 % 0 % -11.11 % -93.48 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 0
Healthcare Sector # 1
Overall Market # 14


Quick Ratio Statistics
High Average Low
10.34 1.02 0
(Sep 30 2019)   (Mar 31 2024)




Financial Statements
Bioforce Nanosciences Holdings's Current Liabilities $ 0 Millions Visit BFNH's Balance sheet
Bioforce Nanosciences Holdings's Cash & cash equivalent $ 0 Millions Visit BFNH's Balance sheet
Source of BFNH's Sales Visit BFNH's Sales by Geography


Cumulative Bioforce Nanosciences Holdings's Quick Ratio

BFNH's Quick Ratio for the trailling 12 Months

BFNH Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -63.12 % -68.21 % -79.78 % -57.11 % -31.86 %
Y / Y Cash & cash equivalent TTM Growth -52.28 % -48.24 % 328.95 % 368.57 % 561.54 %
Quick Ratio TTM 0 0 0.01 0.01 0
Total Ranking TTM # 17 # 17 # # #
Seq. Current Liabilities TTM Growth -12.75 % 26.13 % -49.99 % -32.99 % -24.78 %
Seq. Cash & cash equivalent TTM Growth -6.74 % -46.01 % -0.61 % -4.65 % 1.18 %

Quick ratio ranking by company, industry and sector >> Back to BFNH Financial Strength Comparisons >> Go to Compare BFNH Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in BFNH's Current Liabilities to $0.08 millions, cumulative Quick Ratio